Literature DB >> 30042142

Prescribing biosimilars.

Jeffrey K Aronson1,2, Ben Goldacre3, Robin E Ferner2,4.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30042142     DOI： 10.1136/bmj.k3141

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.

Authors:  Thomas Bo Jensen; Dorthe Bartels; Eva Aggerholm Sædder; Birgitte Klindt Poulsen; Stig Ejdrup Andersen; Mette Marie H Christensen; Lars Nielsen; Hanne Rolighed Christensen
Journal:  Eur J Clin Pharmacol       Date:  2019-11-01       Impact factor: 2.953

2.  Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?

Authors:  Stanton R Mehr; Richard A Brook
Journal:  Pharmaceut Med       Date:  2019-02

3.  Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.

Authors:  Valeria Belleudi; Francesco Trotta; Antonio Addis; Ylenia Ingrasciotta; Valentina Ientile; Michele Tari; Rosa Gini; Maurizio Pastorello; Salvatore Scondotto; Pasquale Cananzi; Giuseppe Traversa; Marina Davoli; Gianluca Trifirò
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

Review 4.  Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists.

Authors:  Jeffrey K Aronson; A Richard Green
Journal:  Br J Clin Pharmacol       Date:  2020-05-13       Impact factor: 4.335

5.  Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.

Authors:  Louise C Druedahl; Sofia Kälvemark Sporrong; Timo Minssen; Hans Hoogland; Marie Louise De Bruin; Marco van de Weert; Anna Birna Almarsdóttir
Journal:  PLoS One       Date:  2022-01-11       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.